Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: The POTTER study

Annarita Tagliaferri, Giulio Feola, Angelo Claudio Molinari, Cristina Santoro, Gianna Franca Rivolta, Dorina Bianca Cultrera, Fabio Gagliano, Ezio Zanon, Maria Elisa Mancuso, Lelia Valdrè, Luciana Mameli, Susanna Amoresano, Prasad Mathew, Antonio Coppola, A. Tagliaferri, G. F. Rivolta, C. Di Perna, G. Feola, A. C. Molinari, L. BanovC. Santoro, M. G. Mazzucconi, D. B. Cultrera, F. Gagliano, E. Zanon, M. E. Mancuso, E. Santagostino, L. Valdrè, G. Rodorigo, L. Mameli, G. Piseddu, A. Coppola, G. Di Minno, N. Negri, S. Amoresano, P. Mathew

Research output: Contribution to journalArticlepeer-review

Abstract

Rigorous evidence is lacking on long-term outcomes of factor VIII (FVIII) prophylaxis initiated in adolescent or adult patients with severe haemophilia A. The prospective, open-label Prophylaxis versus Ondemand Therapy Through Economic Report (POTTER) study (Clinical- Trials.gov NCT01159587) compared long-term late secondary prophylaxis (recombinant FVIII-FS 20–30 IU/kg thrice weekly) with on-demand treatment in patients aged 12 to 55 years with severe haemophilia A. The annual number of joint bleeding episodes (primary endpoint), total bleeding episodes, orthopaedic and radiologic (Pettersson) scores, health-related quality of life (HRQoL), pharmacoeconomic impact, and safety were evaluated over a > 5-year period (2004–2010). Fifty-eight patients were enrolled at 11 centres in Italy; 53 (27 prophylaxis, 26 on demand) were evaluated and stratified into 2 age subgroups (12–25 and 26–55 years). Patients receiving prophylaxis experienced a significantly lower number of joint bleeding episodes vs the on–demand group (annualised bleeding rate, 1.97 vs 16.80 and 2.46 vs 16.71 in younger and older patients, respectively; p=0.0043). Results were similar for total bleeding episodes. Prophylaxis was associated with significantly fewer target joints (p<0.001), better orthopaedic (p=0.0019) and Pettersson (p=0.0177) scores, better HRQoL, and fewer days of everyday activities lost (p<0.0001) but required significantly higher FVIII product consumption. The POTTER study is the first prospective, controlled trial documenting long-term benefits of late secondary prophylaxis in adolescents and adults with severe haemophilia A. The benefits of reduced bleeding frequency, improved joint status, and HRQoL may offset the higher FVIII consumption and costs.

Original languageEnglish
Pages (from-to)35-45
Number of pages11
JournalThrombosis and Haemostasis
Volume114
Issue number1
DOIs
Publication statusPublished - 2015

Keywords

  • Bleeding
  • Haemophilia
  • Haemophilic arthropathy
  • Health-related quality of life
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: The POTTER study'. Together they form a unique fingerprint.

Cite this